Search

Your search keyword '"Cogle CR"' showing total 137 results

Search Constraints

Start Over You searched for: Author "Cogle CR" Remove constraint Author: "Cogle CR"
137 results on '"Cogle CR"'

Search Results

51. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

52. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.

53. Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2.

54. Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes.

55. The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia.

56. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.

57. Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.

58. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.

59. Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.

60. An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats.

61. Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (WISE-CVD).

62. Acute myeloid leukemia in the vascular niche.

63. Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.

64. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

65. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.

66. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.

67. Chemosensitizing AML cells by targeting bone marrow endothelial cells.

68. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.

69. Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.

70. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.

71. Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells.

72. Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.

73. Clinical significance of in vivo cytarabine-induced gene expression signature in AML.

74. Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.

75. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

76. Bone marrow niche in the myelodysplastic syndromes.

77. Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.

78. Incidence and Burden of the Myelodysplastic Syndromes.

79. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

80. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease.

81. Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians.

82. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

83. Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome.

84. Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.

86. Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

87. Functional integration of acute myeloid leukemia into the vascular niche.

88. Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study.

89. Mapping hematopoiesis in a fully regenerative vertebrate: the axolotl.

92. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.

93. A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials.

94. PARP1 is required for chromosomal translocations.

95. Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2.

96. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

97. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.

98. Characteristics of thawed autologous umbilical cord blood.

99. Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study.

100. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.

Catalog

Books, media, physical & digital resources